1. Home
  2. Companies
  3. CMB
  4. Material Events

Cambium Bio (ASX:CMB) — Material Events

ASX:CMB · 12 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 10 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
10
Cambium Bio Advances Phase 3 Trials with Strategic Deals and Fresh FundingHigh
Cambium Bio advances Phase 3 trials, secures strategic partnerships and funding, reports reduced half-year loss
20 Feb 2026 ·Half-Year Financial Report ·85
Cambium Bio Secures $3M Funding Boost to Propel Phase 3 TrialsMedium
Cambium Bio secures A$0.6M R&D refund and A$2.4M strategic placement to advance Phase 3 trials
23 Jan 2026 ·Quarterly Cashflow Report & Business Update ·85
Cambium Bio Secures FDA Nod for Single-Trial Phase 3 and Raises A$2.4M from Major ShareholderHigh
Cambium Bio advances Phase 3 readiness with FDA single-trial pathway confirmation and A$2.4M strategic placement
28 Apr 2026 ·Quarterly Cashflow Report & Business Update ·85
Cambium Bio Secures $2.17M Capital Raise and Strategic Deals to Propel Phase 3 TrialsMedium
Cambium Bio secures R&D tax rebate, strategic partnerships, and completes capital raise to advance Phase 3 trials
27 Oct 2025 ·Quarterly Cashflow Report & Business Update ·85
Cambium Bio Advances Elate Ocular® Phase 3 with $2.12M Funding BoostHigh
Cambium Bio reports $3.84M loss, secures Phase 3 approvals and $2.12M funding for Elate Ocular® trials
29 Aug 2025 ·Appendix 4E and Annual Report ·85
Cambium Bio Expands Reach with Benta SAS for Elate Ocular in Europe and Middle EastMedium
Cambium Bio inks strategic MoU with Benta SAS to commercialise Elate Ocular in Europe and Middle East
5 Sept 2025 ·Strategic Partnership Announcement ·85
Cambium Bio Secures US$2M+ Deal to Expand Dental Biologic ReachMedium
Cambium Bio inks US$2M+ licensing deal with Keke Medtech for dental fibrin biologic
2 Sept 2025 ·Licensing Agreement Announcement ·85
Cambium Bio Secures A$2.4M Boost from Major Shareholder for Phase 3 TrialsMedium
Cambium Bio Raises A$2.4M from Major Shareholder to Fund Phase 3 Trials
20 Jan 2026 ·Capital Raising ·80
Cambium Bio Secures $2.12M to Power Phase 3 Trials of Elate OcularMedium
Cambium Bio advances Phase 3 trials for Elate Ocular with key ethics approvals and secures A$2.12M placement to fund clinical progress
31 July 2025 ·Quarterly Cashflow Report & Business Update ·80
Cambium Bio Secures A$2.12M at 60% Premium to Fund Phase 3 TrialsMedium
Cambium Bio Raises A$2.12M in Placement Led by DJCIC at 60% Premium
30 July 2025 ·Capital Raising ·80
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.